Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B4DC
|
|||
| Former ID |
DAP001236
|
|||
| Drug Name |
Butenafine
|
|||
| Synonyms |
Butenafina; Butenafinum; Mentax; Butenafine HCL; Butenafine [INN]; Butenafine hydrochloride; KP 363; Butenafina [INN-Spanish]; Butenafine (INN); Butenafinum [INN-Latin]; Butop (TN); KP-363; Mentax (TN); N-4-tert-butylbenzyl-N-methyl-1-naphthalene methylamine hydrochloride; N-p-tert-Butylbenzyl-N-methyl-1-naphthalenemethylamine; N-(p-tert-Butylbenzyl)-N-methyl-1-naphthalenemethylamine; 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine; 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Dermatologic infection [ICD-11: 1F28; ICD-10: L00-L08; ICD-9: 680-686] | Approved | [1] | |
| Therapeutic Class |
Antifungal Agents
|
|||
| Company |
Schering-Plough
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H27N
|
|||
| Canonical SMILES |
CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32
|
|||
| InChI |
1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3
|
|||
| InChIKey |
ABJKWBDEJIDSJZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 101828-21-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10267, 603409, 5615389, 8151659, 11342191, 11362374, 11364447, 11367009, 11369571, 11377733, 11487776, 11495367, 14874583, 29215487, 29215488, 29221648, 46506191, 50064067, 51091907, 56313731, 57321348, 79503477, 81040926, 89736078, 92308960, 92712424, 92729938, 93166394, 103261258, 104300725, 124766539, 125336650, 126630107, 126683136, 127381627, 134338475, 135023666, 137006422, 142244396, 144205282, 152034324, 160964425, 162177723, 162201865, 163123303, 164814813, 170465093, 175268882, 175449030, 176484075
|
|||
| ChEBI ID |
CHEBI:3238
|
|||
| ADReCS Drug ID | BADD_D00321 ; BADD_D00322 | |||
| SuperDrug ATC ID |
D01AE23
|
|||
| SuperDrug CAS ID |
cas=101828211
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Butenafine Hydrochloride (adjusted p-values: 9.99E-04). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Butenafine Hydrochloride (adjusted p-values: 1.87E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Butenafine Hydrochloride (adjusted p-values: 9.15E-05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Butenafine Hydrochloride (adjusted p-values: 2.64E-03). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Butenafine Hydrochloride (adjusted p-values: 5.89E-03). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Butenafine Hydrochloride (adjusted p-values: 7.51E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Candida Squalene epoxidase (Candi ERG1) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.